INTERNATIONAL PATENT: ARROWHEAD PHARMACEUTICALS, INC. FILES APPLICATION FOR "RNAI AGENTS FOR DUAL INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) AND PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9), COMPOSITIONS THEREOF AND METHODS OF USE"

GENEVA, Sept. 10 -- ARROWHEAD PHARMACEUTICALS, INC. (177 East Colorado BoulevardSuite 700Pasadena, California 91105) filed a patent application (PCT/US2025/017533) for "RNAI AGENTS FOR DUAL INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) AND PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9), COMPOSITIONS THEREOF, AND METHODS OF USE" on Feb 27, 2025. With publication no. WO/2025/184301, the details related to the patent application was published on Sep 04, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): VAN DYKE, Jonathan (Arrowhead Pharmaceuticals, Inc.502 S. Rosa RoadMADISON, Wiscon...